Tykerb 250 mg Lapatinib Tablets (1 pack / 30 tabs)

Buy Tykerb 250 mg Lapatinib Tablets Online

Tykerb 250 mg Lapatinib Tablets (1 pack / 30 tabs)

At a Glance

Generic Name: Lapatinib

Brand Name: Tykerb 250 mg

Strength & Pack Size: 250 mg tablets, 1 pack / 30 tablets

Dosage Form & Route: Oral film-coated tablets for swallowing whole

Therapeutic Class: Dual HER2/EGFR tyrosine kinase inhibitor (targeted therapy)

Primary Indications: HER2-positive advanced or metastatic breast cancer in selected patients, according to local label

Typical Use in Therapy: Combined with capecitabine or endocrine therapy after trastuzumab or where oral HER2-targeted therapy is appropriate

Mode of Action: Inhibits HER2 (ErbB2) and EGFR (ErbB1) signalling pathways that drive tumour growth and survival

Key Benefits: Oral targeted option that can delay disease progression and control symptoms in carefully selected HER2-positive breast cancer patients

Precautions: Requires monitoring of liver function, cardiac status, diarrhoea, skin reactions and adherence; used only under oncology supervision

Storage: Store in the original pack below 30 °C, protected from moisture and out of reach of children

Product Description

Tykerb 250 mg contains lapatinib, an oral dual tyrosine kinase inhibitor that targets HER2 and EGFR receptors involved in the growth and survival of certain breast cancer cells. It is used under specialist oncology supervision for HER2-positive advanced or metastatic breast cancer, typically in combination with capecitabine or with endocrine therapy in hormone receptor–positive, HER2-positive disease. Tykerb 250 mg lapatinib tablets provide an oral targeted option for patients where continued HER2 blockade remains an important part of the treatment strategy after prior trastuzumab or other systemic therapies.

Each pack of Tykerb 250 mg supplied by Generic Meds Mart contains 30 film-coated tablets, designed to be taken by mouth once daily in a regimen defined by the treating oncologist. Lapatinib therapy is usually part of a broader treatment plan that may include prior or concurrent chemotherapy, endocrine therapy, radiotherapy and HER2-directed monoclonal antibodies. Because of the complexity of HER2-positive metastatic breast cancer management, Tykerb 250 mg should never be started, stopped or adjusted without explicit instruction from the oncology team.

Generic Meds Mart sources Tykerb 250 mg lapatinib tablets only from licensed manufacturers and authorised distributors. Packs are supplied in original, sealed oncology packaging so that hospital or clinic pharmacies can confirm brand, strength, batch number and expiry before dispensing. Outer shipping cartons are neutral and do not reveal that the contents are breast cancer medicines, helping protect patient privacy. Pricing is displayed in USD, which can make planning for ongoing targeted therapy easier for patients and clinics coordinating long-term care.

Key Uses

Within the framework of local approvals and guidelines, Tykerb 250 mg lapatinib tablets are used for HER2-positive breast cancer that is advanced or metastatic and requires continued HER2-targeted therapy. Common situations include combination with capecitabine after progression on regimens containing trastuzumab, or use with an aromatase inhibitor or other endocrine therapy in hormone receptor–positive, HER2-positive advanced disease where an oral regimen is appropriate.

The exact place of Tykerb 250 mg in therapy depends on prior exposure to trastuzumab, pertuzumab, T-DM1 and other HER2-targeted agents, as well as access to newer treatments. Oncologists will weigh the benefits of lapatinib-based regimens against alternatives, considering tumour burden, sites of metastases, comorbidities, prior toxicities and patient preferences. Tykerb 250 mg lapatinib tablets are part of a personalised treatment plan rather than a one-size-fits-all solution.

How Lapatinib Works in Chemotherapy

Lapatinib, the active ingredient in Tykerb 250 mg, is a small-molecule tyrosine kinase inhibitor that targets the intracellular domains of HER2 (ErbB2) and EGFR (ErbB1) receptors. In HER2-positive breast cancer, overexpression or amplification of HER2 drives aggressive tumour growth through downstream signalling pathways that promote proliferation, survival and metastasis.

By selectively binding to and inhibiting HER2 and EGFR tyrosine kinase activity, lapatinib helps block these downstream pathways, including PI3K/AKT and MAPK signalling. This can slow tumour cell proliferation and may trigger apoptosis in HER2-dependent cancer cells. When combined with capecitabine or endocrine therapy, Tykerb 250 mg lapatinib tablets contribute to a multi-pronged strategy that targets both HER2 signalling and DNA replication or hormone-driven growth, depending on the partner agent.

Because lapatinib is an oral agent taken daily, its effect depends heavily on consistent dosing and adherence. Missed doses or treatment interruptions should be discussed with the oncology team so that risk and benefit can be reassessed in context.

Dosage & Administration

Tykerb 250 mg lapatinib tablets must be prescribed and monitored by an oncologist experienced in managing HER2-positive breast cancer. The total daily dose is typically calculated as a specific number of 250 mg tablets taken once daily, with or without food, according to the official product information and the chosen combination regimen. Tablets should be swallowed whole with water and should not be crushed or chewed.

Depending on the protocol, Tykerb 250 mg may be started several days before capecitabine or endocrine therapy or taken concurrently. Patients are usually advised to take lapatinib at the same time each day, under consistent dietary conditions, to reduce variability in exposure. Regular monitoring includes clinical assessment, blood tests (especially liver function tests) and, in some settings, cardiac evaluation such as echocardiography, given that HER2-targeted therapies can affect heart function. Any dose changes, temporary interruptions or treatment discontinuation are determined by the oncology team based on response and tolerability.

Precautions

Before starting Tykerb 250 mg lapatinib tablets, oncologists carefully review liver function, cardiac history, concurrent medicines, gastrointestinal health and potential drug interactions. Lapatinib can cause hepatotoxicity, diarrhoea, skin reactions and, less commonly, decreased left ventricular ejection fraction, so appropriate baseline assessments and ongoing monitoring are important.

Patients are usually advised to report persistent diarrhoea, signs of dehydration, yellowing of the skin or eyes, dark urine, marked fatigue, new or worsening shortness of breath, chest pain or palpitations. Drug–drug interactions must be reviewed, as lapatinib is metabolised via CYP3A4 and may be affected by or affect other medicines. Tykerb 250 mg lapatinib tablets are not recommended during pregnancy, and effective contraception is usually advised during treatment and for a period after stopping therapy. Breastfeeding is generally not recommended while on lapatinib.

Lapatinib Side Effects

Common side effects

Common lapatinib side effects seen with Tykerb 250 mg include diarrhoea, nausea, vomiting, abdominal discomfort, decreased appetite, fatigue, rash or dry skin, palmar-plantar discomfort when combined with capecitabine, and mild elevations in liver enzymes. Many patients also notice mild nail changes or hair thinning.

These effects are often manageable with anti-diarrhoeals, dose interruption or reduction, topical skin care, supportive medicines and careful hydration. The oncology team will provide written instructions on how to manage early diarrhoea and when to seek urgent assessment if symptoms worsen or do not improve.

Serious side effects

Less common but serious lapatinib adverse effects require immediate medical attention. These can include severe hepatotoxicity with significant liver enzyme elevation or jaundice, severe or persistent diarrhoea leading to dehydration and electrolyte disturbances, serious skin reactions, decreased left ventricular ejection fraction with symptoms of heart failure, and rare interstitial lung disease–like reactions.

Patients should seek urgent help if they develop intense, persistent diarrhoea, severe abdominal pain, marked jaundice, dark urine, sudden shortness of breath, chest pain, rapid weight gain with leg swelling, significant rash with blistering or peeling, or any other alarming symptom. The oncology team may need to interrupt Tykerb 250 mg, adjust the dose or switch to an alternative therapy depending on severity and causality.

Storage

Tykerb 250 mg lapatinib tablets should be stored in the original blister pack or bottle at a temperature recommended in the product information, typically below 30 °C, away from moisture and direct heat. The pack should be kept out of sight and reach of children and not transferred to unlabelled containers. Tablets must not be used after the expiry date printed on the carton and blister or bottle label. Unused or expired medicine should be returned to a pharmacy or disposed of according to local guidance for oncology medicines, not thrown in household waste.

Why Buy from Generic Meds Mart

Generic Meds Mart is focused on structured access to targeted oncology medicines such as Tykerb 250 mg lapatinib tablets. We work only with licensed manufacturers and authorised distributors that comply with recognised Good Manufacturing Practice and maintain traceable batch records. Each pack of Tykerb 250 mg supplied by Generic Meds Mart is delivered in sealed original packaging so your oncology pharmacy can verify brand, strength, batch number and expiry before dispensing.

Displaying prices in USD helps patients and clinics budget for ongoing HER2-positive metastatic breast cancer treatment, which often spans many months or longer. Orders are shipped in neutral outer packaging with no explicit reference to breast cancer or lapatinib, and tracking is provided where available so refills can be coordinated before existing supplies run out. Our role is logistical and informational; we do not replace the treating oncologist, and all clinical decisions about using Tykerb 250 mg lapatinib tablets remain strictly with your specialist team.

Order Now

Tykerb 250 mg lapatinib tablets are a targeted oncology medicine that must only be used as part of a clearly defined plan from an experienced oncologist. Before ordering Tykerb 250 mg from Generic Meds Mart, your team should have reviewed pathology reports confirming HER2-positive status, prior treatments, cardiac function and expected benefits and risks of lapatinib-based therapy. You should understand how Tykerb 250 mg will be combined with capecitabine or endocrine therapy, what daily dose you will take, how long each cycle lasts and what monitoring is required.

Once your regimen is agreed, your team can calculate how many packs of Tykerb 250 mg (1 pack / 30 tabs) are needed for your initial course. You can then select the required number of packs on Generic Meds Mart, add them to your cart and complete secure checkout in USD. Medicines are shipped in discreet packaging with full original labelling inside. You should never change, pause or stop Tykerb 250 mg lapatinib tablets without speaking to your oncology team, and any new or severe symptoms should be reported promptly so they can be evaluated in context.

FAQ about Tykerb (Lapatinib)

Q1: What is Tykerb 250 mg used for?
Tykerb 250 mg contains lapatinib, a dual HER2 and EGFR tyrosine kinase inhibitor used under specialist supervision for HER2-positive advanced or metastatic breast cancer, usually in combination with capecitabine or endocrine therapy according to local approvals and guidelines.

Q2: Is Tykerb 250 mg a chemotherapy tablet?
Tykerb 250 mg lapatinib tablets are a form of targeted therapy rather than traditional cytotoxic chemotherapy. They work by blocking HER2 and EGFR signalling pathways in cancer cells. However, they are still powerful anti-cancer medicines with important side effects and monitoring requirements, and they are often used together with chemotherapy or endocrine therapy.

Q3: How long will I need to take Tykerb 250 mg?
Duration of Tykerb 250 mg lapatinib treatment varies from patient to patient. Many people stay on lapatinib therapy as long as their disease is controlled and side effects are manageable. Treatment may be changed or stopped if the cancer progresses or if toxicity becomes unacceptable. Your oncology team will review response, imaging and tolerability regularly to decide how long to continue therapy.

Q4: What should I do if I miss a dose of Tykerb 250 mg?
If you miss a dose of Tykerb 250 mg, follow the instructions in your product leaflet or those provided by your oncology team. In general, you should not double the next dose to make up for a missed one. Instead, you may be told to take the next scheduled dose at the usual time and inform your team if missed doses occur frequently.

Q5: Can Tykerb 250 mg interact with other medicines or supplements?
Yes. Lapatinib is metabolised by liver enzymes such as CYP3A4 and can be affected by or affect certain prescription medicines, over-the-counter products and herbal supplements. Always tell your oncology team and pharmacist about everything you take, including acid-reducing medicines, antibiotics, antifungals, antivirals and herbal remedies, and never start or stop another medicine without checking for potential interactions.